NX-5948
A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 572 patients (estimated)
- Sponsors
- Nurix Therapeutics, Inc.
- Tags
- Bruton's Tyrosine Kinase (BTK) Degrader
- Trial Type
- Treatment
- Last Update
- 2 months ago
- SparkCures ID
- 1374
- NCT Identifier
- NCT05131022
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.